ATL1103 Higher Dose Study
- Higher dose clinical study of ATL1103 in acromegaly patients now closed with clinical study report in preparation
- All 3 patients received a therapeutic benefit from the drug with 2 of the 3 patients achieving the goal of sIGF-I normalisation
- sIGF-I levels normalised in 3rd patient who completed an extended (26 weeks) dosing period
- ATL1103 was well tolerated at the doses tested
Ann: ATL1103 Higher Dose Study-ANP.AX, page-4
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
